PMLiVE5d
J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study
Johnson & Johnson (J&J) and Legend Biotech have shared positive long-term results for their BCMA-directed T-cell ...
PMLiVE6d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission ...
PMLiVE6d
‘Causes That Count, Health’ report – key issues affecting global health
Public health, access to healthcare services, and food and nutrition are some of the most important issues facing people ...
PMLiVE5d
Strategy execution – ensuring it all fits together
Effective brand strategies are like a well-made jigsaw but they can end up looking nothing like the picture that was agreed ...
PMLiVE6d
How women are revolutionising rare disease
Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges ...
PMLiVE4d
Eli Lilly announces new $4.5bn US site for manufacturing and drug development
Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...
PMLiVE4d
NHS England begins newborn screening programme to identify rare genetic conditions
NHS England has announced that hundreds of babies have begun to be tested for over 200 genetic conditions as part of a study led by Genomics England. The Generation Study is evaluating the potential ...
PMLiVE4d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...
PMLiVE5d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
PMLiVE4d
Stats without stories: why journalists aren’t covering your data
During a recent media audit on sickle cell disease, an intriguing pattern emerged that the name ‘Christopher’ was the third most mentioned term. This unexpected finding resonated with me, as I share ...
PMLiVE4d
Top-10 ways for Pharma to leverage AI according to…AI
Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few ...
PMLiVE4d
How patients are transforming cancer care: insights from ESMO on patient-centric oncology
We recently had the privilege of attending the European Society for Medical Oncology (ESMO). With over 40,000 oncology professionals from 177 countries, ESMO stands as a global leader in oncology ...